Acelrx Pharmaceuticals Incの時価総額
Acelrx Pharmaceuticals Incの時価総額は何ですか。
Acelrx Pharmaceuticals Incの時価総額は287.56M$です。
時価総額の定義は何ですか。
時価総額は、取引された会社の発行済株式の市場価値であり、一定期間のb株式に発行済株式数を掛けたものに等しい。
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
NASDAQのセクタHealth Careにおける時価総額の企業と比べるAcelrx Pharmaceuticals Inc
Acelrx Pharmaceuticals Incは何をしますか。
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Acelrx Pharmaceuticals Incと類似の時価総額
- rhipeの時価総額は287.06M$です。
- Invesco Perpetual Select Trust plc Managed Liquidity Share Portfolioの時価総額は287.14M$です。
- CIR S.p.A. Compagnie Industriali Riuniteの時価総額は287.17M$です。
- GRM Overseasの時価総額は287.21M$です。
- Praemiumの時価総額は287.25M$です。
- 1511の時価総額は287.53M$です。
- Acelrx Pharmaceuticals Incの時価総額は287.56M$です。
- MyStateの時価総額は287.59M$です。
- Unichem Laboratoriesの時価総額は287.66M$です。
- SCVX Corpの時価総額は287.79M$です。
- Transphormの時価総額は287.81M$です。
- Hemisphere Media Incの時価総額は287.94M$です。
- Macquarie Global Infrastructure Total Return Fund Incの時価総額は287.95M$です。